While much has been learned about the basic immunology and clinical characteristics of immune thrombocytopenia, many important questions remain with regard to pathogenesis, disease progression, identification of novel therapeutic targets and approaches, and clinical trials that rationalize and optimize use of existing therapies. The answers to these questions are likely to impact our understanding of the pathogenesis and therapeutic targets of autoimmune disease in general.
|Original language||English (US)|
|Journal||Annals of Hematology|
|Issue number||SUPPL. 1|
|State||Published - Jul 2010|
- Autoimmune diseases
- Immune thrombocytopenia
ASJC Scopus subject areas